Cracking The Code: Understanding Analyst Reviews For AtriCure
AtriCure Is Maintained at Buy by Canaccord Genuity
CCORF Maintains AtriCure(ATRC.US) With Buy Rating, Raises Target Price to $61
Express News | AtriCure Inc : Canaccord Genuity Raises Target Price to $61 From $53
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Baiyang Medical (301015.SZ): Currently has established a presence in the high-end medical instrument field with Atricure's atrial fibrillation treatment devices, and products like the full magnetic suspension artificial heart from Tongxin Medical.
HealthTimes reported on November 28th that Baiyang Pharmaceuticals (301015.SZ) stated in a recent investor relations event that the company has currently laid out Atricure's atrial fibrillation treatment equipment, Syncardia's fully magnetically levitated artificial heart, Medisense's ultrasound-guided electromagnetic positioning puncture device, and Wecare's home ECG monitor in the high-end medical instruments field; recently, the company has obtained the exclusive commercial operation rights of ZAP Surgical's ZAP-X Mars Rover radiotherapy surgical robot in mainland China and Hong Kong-Macao region.
Den the Dragon :
